AustralieFrV1, Main, Exploration, bibRecord, 004905

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Identifieur interne : 004905 ( Main/Exploration ); précédent : 004904; suivant : 004906

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Auteurs : Monika M. Schoels [Autriche] ; Désirée Van Der Heijde [Pays-Bas] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho M. Murikama [Japon] ; Norihiro Nishimoto [Japon] ; Josef S. Smolen [Autriche]

Source :

Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-04.

RBID : ISTEX:2153BC56493D306335212683BCCBA81D2025867B

English descriptors

Abstract

Background Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications. Objective To review published evidence on safety and efficacy of IL-6i in inflammatory diseases. Methods We performed systematic literature searches in Medline and Cochrane, screened EULAR and American College of Rheumatology meeting-abstracts, and accessed http://www.clinicaltrials.gov. Results Comprehensive evidence supports the efficacy of tocilizumab in RA in DMARD-naïve patients, and after DMARD- and TNFi-failure. Randomised comparisons demonstrate superiority of tocilizumab in JIA, but not ankylosing spondylitis (AS). Other indications are currently investigated. Additional IL-6i show similar efficacy; safety generally appears acceptable. Conclusions IL-6i is effective and safe in RA and JIA, but not in AS. Preliminary results in other indications need substantiation.

Url:

DOI: 10.1136/annrheumdis-2012-202470

Affiliations:

Allemagne, Australie, Autriche, France, Italie, Japon, Norvège, Pays-Bas, Royaume-Uni, Suisse, États-Unis
Berlin, Hollande-Méridionale, Latium, Vienne (Autriche), État de New York, Île-de-France, Østlandet
Berlin, Leyde, Oslo, Paris, Rome, Vienne (Autriche)

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement</title>
<author><name sortKey="Schoels, Monika M" sort="Schoels, Monika M" uniqKey="Schoels M" first="Monika M" last="Schoels">Monika M. Schoels</name>
</author>
<author><name sortKey="Van Der Heijde, Desiree" sort="Van Der Heijde, Desiree" uniqKey="Van Der Heijde D" first="Désirée" last="Van Der Heijde">Désirée Van Der Heijde</name>
</author>
<author><name sortKey="Breedveld, Ferdinand C" sort="Breedveld, Ferdinand C" uniqKey="Breedveld F" first="Ferdinand C" last="Breedveld">Ferdinand C. Breedveld</name>
</author>
<author><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name>
</author>
<author><name sortKey="Dougados, Maxime" sort="Dougados, Maxime" uniqKey="Dougados M" first="Maxime" last="Dougados">Maxime Dougados</name>
</author>
<author><name sortKey="Emery, Paul" sort="Emery, Paul" uniqKey="Emery P" first="Paul" last="Emery">Paul Emery</name>
</author>
<author><name sortKey="Ferraccioli, Gianfranco" sort="Ferraccioli, Gianfranco" uniqKey="Ferraccioli G" first="Gianfranco" last="Ferraccioli">Gianfranco Ferraccioli</name>
</author>
<author><name sortKey="Gabay, Cem" sort="Gabay, Cem" uniqKey="Gabay C" first="Cem" last="Gabay">Cem Gabay</name>
</author>
<author><name sortKey="Gibofsky, Allan" sort="Gibofsky, Allan" uniqKey="Gibofsky A" first="Allan" last="Gibofsky">Allan Gibofsky</name>
</author>
<author><name sortKey="Gomez Reino, Juan Jesus" sort="Gomez Reino, Juan Jesus" uniqKey="Gomez Reino J" first="Juan Jesus" last="Gomez-Reino">Juan Jesus Gomez-Reino</name>
</author>
<author><name sortKey="Jones, Graeme" sort="Jones, Graeme" uniqKey="Jones G" first="Graeme" last="Jones">Graeme Jones</name>
</author>
<author><name sortKey="Kvien, Tore K" sort="Kvien, Tore K" uniqKey="Kvien T" first="Tore K" last="Kvien">Tore K. Kvien</name>
</author>
<author><name sortKey="Murikama, Miho M" sort="Murikama, Miho M" uniqKey="Murikama M" first="Miho M" last="Murikama">Miho M. Murikama</name>
</author>
<author><name sortKey="Nishimoto, Norihiro" sort="Nishimoto, Norihiro" uniqKey="Nishimoto N" first="Norihiro" last="Nishimoto">Norihiro Nishimoto</name>
</author>
<author><name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2153BC56493D306335212683BCCBA81D2025867B</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2012-202470</idno>
<idno type="url">https://api.istex.fr/document/2153BC56493D306335212683BCCBA81D2025867B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000634</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000634</idno>
<idno type="wicri:Area/Istex/Curation">000634</idno>
<idno type="wicri:Area/Istex/Checkpoint">000215</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000215</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Schoels M:blocking:the:effects</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595140</idno>
<idno type="RBID">PMC:3595140</idno>
<idno type="wicri:Area/Pmc/Corpus">002253</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002253</idno>
<idno type="wicri:Area/Pmc/Curation">002103</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002103</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002037</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002037</idno>
<idno type="wicri:Area/Ncbi/Merge">001030</idno>
<idno type="wicri:Area/Ncbi/Curation">001030</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001030</idno>
<idno type="wicri:doubleKey">0003-4967:2012:Schoels M:blocking:the:effects</idno>
<idno type="wicri:Area/Main/Merge">004A29</idno>
<idno type="wicri:Area/Main/Curation">004905</idno>
<idno type="wicri:Area/Main/Exploration">004905</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement</title>
<author><name sortKey="Schoels, Monika M" sort="Schoels, Monika M" uniqKey="Schoels M" first="Monika M" last="Schoels">Monika M. Schoels</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>2nd Department of Medicine, Center for Rheumatic Disease, Hietzing Hospital, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Der Heijde, Desiree" sort="Van Der Heijde, Desiree" uniqKey="Van Der Heijde D" first="Désirée" last="Van Der Heijde">Désirée Van Der Heijde</name>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Rheumatology, Leiden University Medical Center, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Breedveld, Ferdinand C" sort="Breedveld, Ferdinand C" uniqKey="Breedveld F" first="Ferdinand C" last="Breedveld">Ferdinand C. Breedveld</name>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Rheumatology, Leiden University Medical Center, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, Charité, Free University and Humboldt University, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dougados, Maxime" sort="Dougados, Maxime" uniqKey="Dougados M" first="Maxime" last="Dougados">Maxime Dougados</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Rheumatology, Cochin Hospital, René Descartes University, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Emery, Paul" sort="Emery, Paul" uniqKey="Emery P" first="Paul" last="Emery">Paul Emery</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Academic Unit of Musculoskeletal Diseases, Leeds University, Leeds</wicri:regionArea>
<wicri:noRegion>Leeds</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ferraccioli, Gianfranco" sort="Ferraccioli, Gianfranco" uniqKey="Ferraccioli G" first="Gianfranco" last="Ferraccioli">Gianfranco Ferraccioli</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Division of Rheumatology and Internal Medicine—CIC, Catholic University of the Sacred Heart—School of Medicine, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gabay, Cem" sort="Gabay, Cem" uniqKey="Gabay C" first="Cem" last="Gabay">Cem Gabay</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>Division of Rheumatology, University Hospital, University of Geneva, Geneva</wicri:regionArea>
<wicri:noRegion>Geneva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gibofsky, Allan" sort="Gibofsky, Allan" uniqKey="Gibofsky A" first="Allan" last="Gibofsky">Allan Gibofsky</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gomez Reino, Juan Jesus" sort="Gomez Reino, Juan Jesus" uniqKey="Gomez Reino J" first="Juan Jesus" last="Gomez-Reino">Juan Jesus Gomez-Reino</name>
<affiliation><wicri:noCountry code="subField">Santiago</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Jones, Graeme" sort="Jones, Graeme" uniqKey="Jones G" first="Graeme" last="Jones">Graeme Jones</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Musculoskeletal Unit, Menzies Research Institute, University of Tasmania, Hobart</wicri:regionArea>
<wicri:noRegion>Hobart</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kvien, Tore K" sort="Kvien, Tore K" uniqKey="Kvien T" first="Tore K" last="Kvien">Tore K. Kvien</name>
<affiliation wicri:level="3"><country xml:lang="fr">Norvège</country>
<wicri:regionArea>Department of Rheumatology, Diakonhjemmet Hospital, Oslo</wicri:regionArea>
<placeName><settlement type="city">Oslo</settlement>
<region nuts="2">Østlandet</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Murikama, Miho M" sort="Murikama, Miho M" uniqKey="Murikama M" first="Miho M" last="Murikama">Miho M. Murikama</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Laboratory of Immune Regulation, Wakayama Medical University, Wakayama</wicri:regionArea>
<wicri:noRegion>Wakayama</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nishimoto, Norihiro" sort="Nishimoto, Norihiro" uniqKey="Nishimoto N" first="Norihiro" last="Nishimoto">Norihiro Nishimoto</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Laboratory of Immune Regulation, Wakayama Medical University, Wakayama</wicri:regionArea>
<wicri:noRegion>Wakayama</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>2nd Department of Medicine, Center for Rheumatic Disease, Hietzing Hospital, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-04">2013-04</date>
<biblScope unit="volume">72</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="583">583</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept</term>
<term>Abstract number</term>
<term>Advisory board meetings</term>
<term>American college</term>
<term>Ankylosing spondylitis</term>
<term>Antirheumatic drugs</term>
<term>Arthritis</term>
<term>Biologics</term>
<term>Clinical practice</term>
<term>Clinical trial</term>
<term>Cochrane</term>
<term>Combination therapy</term>
<term>Disease activity</term>
<term>Dmard</term>
<term>Dmards</term>
<term>Epidemiological</term>
<term>Epidemiological research</term>
<term>Grant support</term>
<term>Idiopathic</term>
<term>Idiopathic arthritis</term>
<term>Inadequate response</term>
<term>Juvenile idiopathic arthritis</term>
<term>Methotrexate</term>
<term>Methotrexate therapy</term>
<term>Monoclonal antibody</term>
<term>Monotherapy</term>
<term>Nishimoto</term>
<term>Online</term>
<term>Postmarketing surveillance</term>
<term>Preliminary results</term>
<term>Presentation number</term>
<term>Radiographic</term>
<term>Randomised</term>
<term>Randomised comparisons</term>
<term>Randomized</term>
<term>Receptor</term>
<term>Receptor inhibition</term>
<term>Remission</term>
<term>Remission rates</term>
<term>Response rates</term>
<term>Retrospective study</term>
<term>Rheum</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid arthritis patients</term>
<term>Rheumatol</term>
<term>Rheumatology</term>
<term>Roche</term>
<term>Smolen</term>
<term>Systematic review</term>
<term>Tnfi</term>
<term>Tocilizumab</term>
<term>Tocilizumab monotherapy</term>
<term>Tocilizumab therapy</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Abatacept</term>
<term>Abstract number</term>
<term>Advisory board meetings</term>
<term>American college</term>
<term>Ankylosing spondylitis</term>
<term>Antirheumatic drugs</term>
<term>Arthritis</term>
<term>Biologics</term>
<term>Clinical practice</term>
<term>Clinical trial</term>
<term>Cochrane</term>
<term>Combination therapy</term>
<term>Disease activity</term>
<term>Dmard</term>
<term>Dmards</term>
<term>Epidemiological</term>
<term>Epidemiological research</term>
<term>Grant support</term>
<term>Idiopathic</term>
<term>Idiopathic arthritis</term>
<term>Inadequate response</term>
<term>Juvenile idiopathic arthritis</term>
<term>Methotrexate</term>
<term>Methotrexate therapy</term>
<term>Monoclonal antibody</term>
<term>Monotherapy</term>
<term>Nishimoto</term>
<term>Online</term>
<term>Postmarketing surveillance</term>
<term>Preliminary results</term>
<term>Presentation number</term>
<term>Radiographic</term>
<term>Randomised</term>
<term>Randomised comparisons</term>
<term>Randomized</term>
<term>Receptor</term>
<term>Receptor inhibition</term>
<term>Remission</term>
<term>Remission rates</term>
<term>Response rates</term>
<term>Retrospective study</term>
<term>Rheum</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid arthritis patients</term>
<term>Rheumatol</term>
<term>Rheumatology</term>
<term>Roche</term>
<term>Smolen</term>
<term>Systematic review</term>
<term>Tnfi</term>
<term>Tocilizumab</term>
<term>Tocilizumab monotherapy</term>
<term>Tocilizumab therapy</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications. Objective To review published evidence on safety and efficacy of IL-6i in inflammatory diseases. Methods We performed systematic literature searches in Medline and Cochrane, screened EULAR and American College of Rheumatology meeting-abstracts, and accessed http://www.clinicaltrials.gov. Results Comprehensive evidence supports the efficacy of tocilizumab in RA in DMARD-naïve patients, and after DMARD- and TNFi-failure. Randomised comparisons demonstrate superiority of tocilizumab in JIA, but not ankylosing spondylitis (AS). Other indications are currently investigated. Additional IL-6i show similar efficacy; safety generally appears acceptable. Conclusions IL-6i is effective and safe in RA and JIA, but not in AS. Preliminary results in other indications need substantiation.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Autriche</li>
<li>France</li>
<li>Italie</li>
<li>Japon</li>
<li>Norvège</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
<li>États-Unis</li>
</country>
<region><li>Berlin</li>
<li>Hollande-Méridionale</li>
<li>Latium</li>
<li>Vienne (Autriche)</li>
<li>État de New York</li>
<li>Île-de-France</li>
<li>Østlandet</li>
</region>
<settlement><li>Berlin</li>
<li>Leyde</li>
<li>Oslo</li>
<li>Paris</li>
<li>Rome</li>
<li>Vienne (Autriche)</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Gomez Reino, Juan Jesus" sort="Gomez Reino, Juan Jesus" uniqKey="Gomez Reino J" first="Juan Jesus" last="Gomez-Reino">Juan Jesus Gomez-Reino</name>
</noCountry>
<country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Schoels, Monika M" sort="Schoels, Monika M" uniqKey="Schoels M" first="Monika M" last="Schoels">Monika M. Schoels</name>
</region>
<name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name>
<name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name>
</country>
<country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Van Der Heijde, Desiree" sort="Van Der Heijde, Desiree" uniqKey="Van Der Heijde D" first="Désirée" last="Van Der Heijde">Désirée Van Der Heijde</name>
</region>
<name sortKey="Breedveld, Ferdinand C" sort="Breedveld, Ferdinand C" uniqKey="Breedveld F" first="Ferdinand C" last="Breedveld">Ferdinand C. Breedveld</name>
</country>
<country name="Allemagne"><region name="Berlin"><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name>
</region>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Dougados, Maxime" sort="Dougados, Maxime" uniqKey="Dougados M" first="Maxime" last="Dougados">Maxime Dougados</name>
</region>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Emery, Paul" sort="Emery, Paul" uniqKey="Emery P" first="Paul" last="Emery">Paul Emery</name>
</noRegion>
</country>
<country name="Italie"><region name="Latium"><name sortKey="Ferraccioli, Gianfranco" sort="Ferraccioli, Gianfranco" uniqKey="Ferraccioli G" first="Gianfranco" last="Ferraccioli">Gianfranco Ferraccioli</name>
</region>
</country>
<country name="Suisse"><noRegion><name sortKey="Gabay, Cem" sort="Gabay, Cem" uniqKey="Gabay C" first="Cem" last="Gabay">Cem Gabay</name>
</noRegion>
</country>
<country name="États-Unis"><region name="État de New York"><name sortKey="Gibofsky, Allan" sort="Gibofsky, Allan" uniqKey="Gibofsky A" first="Allan" last="Gibofsky">Allan Gibofsky</name>
</region>
</country>
<country name="Australie"><noRegion><name sortKey="Jones, Graeme" sort="Jones, Graeme" uniqKey="Jones G" first="Graeme" last="Jones">Graeme Jones</name>
</noRegion>
</country>
<country name="Norvège"><region name="Østlandet"><name sortKey="Kvien, Tore K" sort="Kvien, Tore K" uniqKey="Kvien T" first="Tore K" last="Kvien">Tore K. Kvien</name>
</region>
</country>
<country name="Japon"><noRegion><name sortKey="Murikama, Miho M" sort="Murikama, Miho M" uniqKey="Murikama M" first="Miho M" last="Murikama">Miho M. Murikama</name>
</noRegion>
<name sortKey="Nishimoto, Norihiro" sort="Nishimoto, Norihiro" uniqKey="Nishimoto N" first="Norihiro" last="Nishimoto">Norihiro Nishimoto</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004905 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004905 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:2153BC56493D306335212683BCCBA81D2025867B
   |texte=   Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.